Cardiovascular Effects of Smoking Cessation Drugs

World Health Organization. (2011). WHO report on the global tobacco epidemic, 2011: war- ning about the dangers of tobacco. World Health Organization.

WHO Global Report: Mortality Attributable to Tobacco. http://whqlibdoc.who.int/publicati- ons/2012/9789241564434_eng.pdf. World Health Organisation, 2012.

Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and be- nefits of cessation in the United States. The New England Journal of Medicine. 2013;368(4): 341-350. doi:10.1056/NEJMsa1211128

WHO global report on trends in prevalence of tobacco use 2000–2025, third edition [In- ternet]. [cited 2023 Jan 3]. Available from: https://www.who.int/publications-detail-redirect/ who-global-report-on-trends-in-prevalence-of-tobacco-use-2000-2025-third-edition

de Beyer J, Lovelace C, Yürekli A. Poverty and tobacco. Tobacco Control. 2001;10(3): 210-211. doi:10.1136/tc.10.3.210

de Silva V, Samarasinghe D, Hanwella R. Association between concurrent alcohol and to- bacco use and poverty. Drug and Alcohol Review. 2011;30(1): 69-73. doi:10.1111/j.1465- 3362.2010.00202.x

Blosnich J, Lee JG, Horn K. A systematic review of the aetiology of tobacco disparities for sexu- al minorities. Tobacco Control. 2013;22(2): 66-73. doi:10.1136/tobaccocontrol-2011-050181

Lee JG, Griffin GK, Melvin CL. Tobacco use among sexual minorities in the USA, 1987 to May 2007: a systematic review. Tobacco Control. 2009;18(4): 275-282. doi:10.1136/tc.2008.028241

Farley SM, Maroko AR, Suglia SF, et al. The Influence of tobacco retailer density and poverty on tobacco use in a densely populated urban environment. Public Health Reports. 2019;134(2): 164-171. doi:10.1177/0033354918824330

Burke JD, Loeber R, White HR, et al. Inattention as a key predictor of tobacco use in adolescen- ce. Journal of Abnormal Psychology. 2007;116(2): 249-259. doi:10.1037/0021-843X.116.2.249

Pang S, Subramaniam M, Abdin E, et al. Prevalence and predictors of tobacco use in the elder- ly. International Journal of Geriatric Psychiatry. 2016;31(7): 716-722. https://doi.org/10.1002/ gps.4382

Cullen KA, Ambrose BK, Gentzke AS, et al. Notes from the Field: Use of Electronic Cigarettes and Any Tobacco Product Among Middle and High School Students-United States, 2011- 2018. Morbidity and Mortality Weekly Report. 2018;67(45): 1276-1277. doi:10.15585/mmwr. mm6745a5

Khouja JN, Suddell SF, Peters SE, et al. Is e-cigarette use in non-smoking young adults associ- ated with later smoking? A systematic review and meta-analysis. Tobacco Control. 2020;30(1): 8-15. doi:10.1136/tobaccocontrol-2019-055433

O’Brien D, Long J, Quigley J, et al. Association between electronic cigarette use and tobacco cigarette smoking initiation in adolescents: a systematic review and meta-analysis. BMC Pub- lic Health. 2021;21(1): 954. doi:10.1186/s12889-021-10935-1

National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smo- king and Health. The health consequences of smoking-50 years of progress: a report of the Surgeon General. http://www.ncbi.nlm.nih.gov/pubmed/24455788. Published 2014. Accessed January 4, 2023.

Centers for Disease Control and Prevention (US); National Center for Chronic Disease Pre- vention and Health Promotion (US); Office on Smoking and Health (US). How tobacco smo- ke causes disease: the biology and behavioral basis for smoking-attributable disease. 2010. ht- tps://www.ncbi.nlm.nih.gov/books/NBK53017/. Published 2010. Accessed January 12, 2023.

Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure to cigarette smo- ke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Di- sease Section Leadership Council and Early Career Councils of the American College of Car- diology. Journal of the American College of Cardiology. 2015;66(12): 1378-1391. doi:10.1016/j. jacc.2015.07.037

The World Health Organization. The World Health Report; 1999.

Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368(9536): 647-658. doi:10.1016/S0140-6736(06)69249-0

Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myo- cardial infarction with left ventricular dysfunction. The American Journal of Cardiology. 2010;106(7): 911-916. doi:10.1016/j.amjcard.2010.05.021

D’Alessandro A, Boeckelmann I, Hammwhoner M, et al. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. European Journal of Preventive Cardiology. 2012;19(3): 297- 305. doi:10.1177/1741826711411738

Luoto R, Uutela A, Puska P. Occasional smoking increases total and cardiovascular mortality among men. Nicotine & Tobacco Research: Official Journal of the Society for Research On Nico- tine and Tobacco. 2000;2(2): 133-139. doi:10.1080/713688127

Puranik R, Celermajer DS. Smoking and endothelial function. Progress in Cardiovascular Diseases. 2003;45(6): 443-458. doi:10.1053/pcad.2003.YPCAD13

Di Angelantonio S, Matteoni C, Fabbretti E, et al. Molecular biology and electrophysiology of neuronal nicotinic receptors of rat chromaffin cells. The European Journal of Neuroscience. 2003;17(11): 2313-2322. doi:10.1046/j.1460-9568.2003.02669.x

Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implica- tions for treatment. Progress in the Cardiovascular Diseases. 2003;46(1): 91-111. doi:10.1016/ s0033-0620(03)00087-2

Burke A, Fitzgerald GA. Oxidative stress and smoking-induced vascular injury. Progress in Cardiovascular Diseases. 2003;46(1): 79-90. doi:10.1016/s0033-0620(03)00076-8

Kannel WB, D’Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardio- vascular disease: insights from the Framingham Study. American Heart Journal. 1987;113(4): 1006-1010. doi:10.1016/0002-8703(87)90063-9

Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2007;298(22): 2654-2664. doi:10.1001/ jama.298.22.2654

Cullen P, Schulte H, Assmann G. Smoking, lipoproteins and coronary heart disease risk. Data from the Munster Heart Study (PROCAM). European Heart Journal. 1998;19(11): 1632-1641. doi:10.1053/euhj.1998.1086

Talukder MA, Johnson WM, Varadharaj S, et al. Chronic cigarette smoking causes hyper- tension, increased oxidative stress, impaired NO bioavailability, endothelial dysfunction, and cardiac remodeling in mice. American Journal of Physiology. Heart and Circulatory Physiology. 2011;300(1): H388-H396. doi:10.1152/ajpheart.00868.2010

Huerta JM, Tormo MJ, Gavrila D, et al. Cardiovascular risk estimated after 13 years of fol- low-up in a low-incidence Mediterranean region with high-prevalence of cardiovascular risk factors. BMC Public Health. 2010;10: 640. doi:10.1186/1471-2458-10-640

Hata J, Doi Y, Ninomiya T, et al. Combined effects of smoking and hypercholesterolemia on the risk of stroke and coronary heart disease in Japanese: the Hisayama study. Cerebrovascular Diseases. 2011;31(5): 477-484. doi:10.1159/000324392

Bengtsson I, Karlson BW, Herlitz J, et al. A 14-year follow-up study of chest pain patients inc- luding stress hormones and mental stress at index event. International Journal of Cardiology. 2012;154(3): 306-311. doi:10.1016/j.ijcard.2010.09.056

Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438): 937-952. doi:10.1016/S0140-6736(04)17018-9

Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1): 86-97. doi:10.1001/jama.290.1.86

Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for pa- tients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113(19): 2363-2372. doi:10.1161/ CIRCULATIONAHA.106.174516

Mohiuddin SM, Mooss AN, Hunter CB, et al. Intensive smoking cessation intervention redu- ces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131(2): 446-452. doi:10.1378/chest.06-1587

Critchley J, Capewell S. Smoking cessation for the secondary prevention of coro- nary heart disease. The Cochrane Database of Systematic Reviews. 2004;(1): CD003041. doi:10.1002/14651858.CD003041.pub2

Gerber Y, Rosen LJ, Goldbourt U, et al. Smoking status and long-term survival after first acute myocardial infarction: a population-based cohort study. Journal of the American College of Cardiology. 2009;54(25): 2382-2387. doi:10.1016/j.jacc.2009.09.020

Barth J, Critchley J, Bengel J. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database of Systematic Reviews. 2008;(1): CD006886. doi:10.1002/14651858.CD006886

Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily prac- tice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667): 929-940. doi:10.1016/S0140-6736(09)60330-5

Quist-Paulsen P, Gallefoss F. Randomised controlled trial of smoking cessation intervention after admission for coronary heart disease. BMJ. 2003;327(7426): 1254-1257. doi:10.1136/ bmj.327.7426.1254

Colivicchi F, Mocini D, Tubaro M, et al. Effect of smoking relapse on outcome after acute co- ronary syndromes. The American Journal of Cardiology. 2011;108(6): 804-808. doi:10.1016/j. amjcard.2011.04.033

He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart disease–a meta analysis of epidemiologic studies. The New England Journal of Medicine. 1999;340(12): 920-926. doi:10.1056/NEJM199903253401204

Oberg M, Jaakkola MS, Woodward A, et al. Worldwide burden of disease from exposure to se- cond hand smoke: a retrospective analysis of data from 192 countries. Lancet. 2011;377(9760): 139-146. doi:10.1016/S0140-6736(10)61388-8

Meyers DG, Neuberger JS, He J. Cardiovascular effect of bans on smoking in public pla- ces: a systematic review and meta-analysis. Journal of the American College of Cardiology. 2009;54(20): 1249-1255. doi:10.1016/j.jacc.2009.07.022

Callinan JE, Clarke A, Doherty K, et al. Legislative smoking bans for reducing secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database of Systematic Reviews. 2010;(4): CD005992. doi:10.1002/14651858.CD005992.pub2

Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug and Alcohol Dependence. 1993;33(1): 23-29. doi:10.1016/0376-8716(93)90030-t

Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine & Tobacco Research: Official Journal of the So- ciety for Research on Nicotine and Tobacco. 2000;2(1): 19-37. doi:10.1080/14622200050011277

Subramaniyan M, Dani JA. Dopaminergic and cholinergic learning mechanisms in nicotine addiction. Annals of the New York Academy of Sciences. 2015;1349(1): 46-63. doi:10.1111/ nyas.12871

Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of alpha4* receptors: Sufficient for reward, tolerance, and sensitization. Science. 2004;306(5698): 1029-1032. doi:10.1126/ science.1099420

Benowitz NL. Nicotine addiction. The New England Journal of Medicine. 2010;362(24): 2295 2303. doi:10.1056/NEJMra0809890

Shiffman S, West R, Gilbert D. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco. 2004;6(4): 599-614. doi:10.1080/146222004100 01734067

Fiore MC, Jaen CR, Baker TB, et al. [Accessed February 12, 2023] Treating tobacco use and dependence: 2008 update. clinical practice guideline: U.S. Department of Health and Human Services, Public Health Service. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?ri- d=hstat2.chapter.28163.

Stead L, Koipillai P, Fanshawe TR, et al. Combined pharmacotherapy and behavioural in- terventions for smoking cessation. Cochrane Database of Systematic Reviews. 2016;3(3): CD008286. doi:10.1002/14651858.CD008286.pub3

Leone FT, Evers-Casey S. Behavioral Interventions in Tobacco Dependence. Primary Care.

2009;36(3): 489-507. doi:10.1016/j.pop.2009.04.002

Lydon-Staley DM, Schnoll RA, Hitsman B, et al. The Network Structure of Tobacco Wit- hdrawal in a Community Sample of Smokers Treated With Nicotine Patch and Behavioral Counseling. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nico- tine and Tobacco. 2020;22(3): 408-414. doi:10.1093/ntr/nty250

Lydon-Staley DM, Cornblath EJ, Blevins AS, et al. Modeling brain, symptom, and behavior in the winds of change. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology. 2021;46(1): 20-32. doi:10.1038/s41386-020-00805-6

Croghan GA, Sloan JA, Croghan IT, et al. Comparison of nicotine patch alone versus ni- cotine nasal spray alone versus a combination for treating smokers: A minimal interven- tion, randomized multicenter trial in a nonspecialized setting. Nicotine & Tobacco Resear- ch: Official Journal of the Society for Research on Nicotine and Tobacco. 2003;5(2): 181-187. doi:10.1080/1462220031000073252

Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. New England Jour- nal of Medicine. 2002;346(7): 506-512. doi:10.1056/NEJMcp012279

Shiffman S, Sembower MA, Rohay JM, et al. Assigning Dose of Nicotine Gum by Time to First Cigarette. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco. 2013;15(2): 407-412. doi:10.1093/ntr/nts141

Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation.

Archives of Internal Medicine. 2002;162(11): 1267-1276. doi:10.1001/archinte.162.11.1267

Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Archives of Internal Medicine. 2009;169(22): 2148-2155. doi:10.1001/archinternmed.2009.426

Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. The Cochrane Database of Systematic Reviews. 2012;11:CD000146. doi:10.1002/14651858. CD000146.pub4.

Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994;271(24): 1940-1947.doi:10.1001/ jama.1994.03510480064036

US Department of Health and Human Services, Public Health Services, Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: clinical practice guideline. Rock- ville: USDept of Health and Human Services, Public Health Service; 2000. p. 25-90.

Rigotti NA, Eagle KA. Atrial fibrillation while chewing nicotine gum. JAMA. 1986;255(8): 1018. doi:10.1001/jama.1986.03370080039014

Dacosta A, Guy JM, Tardy B, et al. Myocardial infarction and nicotine patch: a contributing or causative factor?. European Heart Journal. 1993;14(12): 1709-1711. doi:10.1093/eurhe- artj/14.12.1709

Pierce JR Jr. Stroke following application of a nicotine patch. The Annals of Pharmacotherapy. 1994;28(3): 402. doi:10.1177/106002809402800320

Ottervanger JP, Festen JM, de Vries AG, et al. Acute myocardial infarction while using the nicotine patch. Chest. 1995;107(6): 1765-1766. doi:10.1378/chest.107.6.1765

Ropchan GV, Sanfilippo AJ, Ford SE. Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. The Canadian Journal of Cardiology. 1997;13(5): 525-528.

Shiffman S, Ferguson SG, Hellebusch SJ. Physicians’ counseling of patients when prescribing nicotine replacement therapy. Addictive Behaviors. 2007;32(4): 728-739. doi:10.1016/j.add- beh.2006.06.021

Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preven- ting, and treating tobacco addiction. Clinical Pharmacology Therapeutics. 2008;83(4): 531- 541. doi:10.1038/clpt.2008.3

Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. Journal of the American College of Cardiology. 1997;29(7): 1422-1431. doi:10.1016/s0735-1097(97)00079-x

Blann AD, Steele C, McCollum CN. The influence of smoking and of oral and transdermal nicotine on blood pressure, and haematology and coagulation indices. Thrombosis and Hae- mostasis. 1997;78(3): 1093-1096. doi: 10.1055/s-0038-1657692

Lucini D, Bertocchi F, Malliani A, et al. Autonomic effects of nicotine patch administration in habitual cigarette smokers: a double-blind, placebo-controlled study using spectral analysis of RR interval and systolic arterial pressure variabilities. Journal of Cardiovascular Pharmaco- logy. 1998;31(5): 714-720. doi:10.1097/00005344-199805000-00010

Zevin S, Jacob 3rd P, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clinical Pharmacology and Therapeutics. 1998;64(1): 87-95. doi:10.1016/ S0009 9236(98)90026-1

Mundal HH, Hjemdahl P, Ghesdal K. Acute effects of low dose nicotine gum on platelet function in non-smoking hypertensive and normotensive men. European Journal of Clinical Pharmacology. 1995;47(5): 411-416. doi:10.1007/BF00196854

Benowitz NL, Fitzgerald GA, Wilson M, et al. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. Journal of the American College of Cardiology. 1993;22(4): 1159-1167. doi:10.1016/0735-1097(93)90431-y

Foulds J, Stapleton J, Feyerabend C, et al. Effect of transdermal nicotine patches on ciga- rette smoking: a double blind crossover study. Psychopharmacology. 1992;106(3): 421-427. doi:10.1007/BF02245429

Fishbein L, O’Brien P, Hutson A, et al. Pharmacokinetics and pharmacodynamic effects of ni- cotine nasal spray devices on cardiovascular and pulmonary function. Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research. 2000;48(6): 435-440.

Yugar-Toledo JC, Ferreira-Melo SE, Sabha M, et al. Blood pressure circadian rhythm and en- dothelial function in heavy smokers: acute effects of transdermal nicotine. Journal of Clinical Hypertension. 2005;7(12): 721-728. doi:10.1111/j.1524-6175.2005.04597.x

Khoury Z, Comans P, Keren A, et al. Effects of transdermal nicotine patches on ambulatory ECG monitoring findings: A double-blind study in healthy smokers. Cardiovascular Drugs and Therapy. 1996;10(2): 179-184. doi:10.1007/BF00823596

Tanus-Santos JE, Toledo JCY, Cittadino M, et al. Cardiovascular effects of transdermal ni- cotine in mildly hypertensive smokers. American Journal of Hypertension. 2001;14(7 pt 1): 610-614. doi:10.1016/s0895-7061(01)01301-2

Benowitz NL, Hansson A, Jacob P 3rd. Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension. 2002;39(6): 1107-1112. doi:10.1161/01. hyp.0000018825.76673.ea

Kimmel SE, Berlin JA, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in the general population. Journal of the American College of Cardiology. 2001;37(5): 1297-1302. doi:10.1016/s0735-1097(01)01124-x

Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adver- se effects associated with the transdermal nicotine patch. Drug Safety. 1998;18(4): 297-308. doi:10.2165/00002018-199818040-00005

Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. The New England Journal of Medicine. 1996;335(24): 1792-1798. doi:10.1056/NEJM199612123352402

Meine TJ, Patel MR, Washam JB, et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. The American Journal of Cardiology. 2005;95(8): 976-978. doi:10.1016/j.amjcard.2004.12.039

Woolf KJ, Zabad MN, Post JM, et al. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. The American Journal of Cardiology. 2012;110(7): 968-970. doi:10.1016/j.amjcard.2012.05.028

Mahmarian JJ, Moye LA, Nasser GA, et al. Nicotine patch therapy in smoking cessation re- duces the extent of exercise-induced myocardial ischemia. Journal of the American College of Cardiology. 1997;30(1): 125-130. doi:10.1016/s0735-1097(97)00128-9

Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. 2014;129(1): 28-41. doi:10.1161/ CIRCULATIONAHA.113.003961

Cardiac adverse effects of nicotine replacement therapy. Prescrire International. 2015;24(166): 292-293.

Silva AP, Scholz J, Abe TO, et al. Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting. BMC Cardiovascular Disorders. 2016;16: 2. doi:10.1186/s12872-015-0180-4.

Suissa K, Larivière J, Eisenberg MJ, et al. Efficacy and Safety of Smoking Cessation Inter- ventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials. Circulation. Cardiovascular Quality and Outcomes. 2017;10(1): e002458. doi:10.1161/CIRCOUTCOMES.115.002458.

Benowitz NL, Pipe A, West R, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(5): 622-631. doi: 10.1001/jamainternmed.2018.0397.

Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clinic Proceedings. 2005;80(5): 652-656. doi:10.4065/80.5.652

Pickering TG. Effects of stress and behavioral interventions in hypertension–the effects of smoking and nicotine replacement therapy on blood pressure. Journal of Clinical Hypertensi- on. 2001;3(5): 319-321. doi: 10.1111/j.1524-6175.2001.00483.x

How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking Attri- butable Disease: A Report of the Surgeon General. Rockville, MD: Department of Health and Human Services, Public Health Service, Office of Surgeon General; 2010.

Covey LS, Sullivan MA, Johnston JA, et al. Advances in non-nicotine therapy for smoking cessation. Drugs. 2000;59(1): 17-31. doi:10.2165/00003495-200059010-00003

Benowitz NL, Peng MW. Non-nicotine pharmacotherapy for smoking cessation: Mecha- nisms and prospects. CNS Drugs. 2000;13: 265-285. doi: https://doi.org/10.2165/00023210- 200013040-00004

Di Chiara G. Role of dopamine in the behavioral actions of nicotine reated to addiction. Euro- pean Journal of Pharmacology. 2000;393(1-3): 295-314. doi:10.1016/s0014-2999(00)00122-9

Jain R, Mukherjee K. Biologial basis of nicotine addiction. Indian Journal of Pharmacology. 2003;35(5): 281-289.

Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. Journal of Pharma- cology and Experimental Therapeutics. 2000;295(1): 321-327.

Jimenez RC. Pharmacologial treatment for smoking cessation. European Respiratory Monog- raph. 2008;42: 74-97.

Wilkes S. The use of bupropion SR in cigarette smoking cessation. International Journal of Chronic Obstructive Pulmonary Disease. 2008;3(1): 45-53. doi:10.2147/copd.s1121

Hays JT, Ebbert JO. Bupropion sustained release for treatment of tobacco dependence. Mayo Clinic Proceedings. 2003;78(8): 1020-1024. doi:10.4065/78.8.1020

Evren EC. Sigara bırakma tedavisinde antidepresanların kullanımı: Bu tedavide bupropion’un yeri. Klinik Psikofarmakoloji Bülteni. 2001;3(11): 198-211.

Hughes JR, Stead LF ,Hartmann-Boyce J, et al. Antidepressants for smoking cessation. The Cochrane Database of Systematic Reviews. 2014;2014(1): CD000031. doi:10.1002/14651858. CD000031. pub4.

Prochaska JJ, Benowitz NL. The past, present, and future of nicotine addiction therapy. Annu- al Review of Medicine. 2016;67: 467-486. doi:10.1146/annurev-med-111314-033712

Holm KJ, Spencer CM. Bupropion: A review of its use in the management of smoking cessa- tion. Drugs. 2000;59(4): 1007-1024. doi:10.2165/00003495-200059040-00019

Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs. 2002;62(Suppl 2): 25-35. doi:10.2165/00003495-200262002-00003

Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. The Cochrane Database of Systematic Reviews. 2013;2013(5): CD009329. doi: 10.1002/14651858.CD009329.pub2.

Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Annals of Internal Medici- ne. 2001;135(6): 423-433. doi:10.7326/0003-4819-135-6-200109180-00011

Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and pla- cebo for smoking cessation. The New England Journal of Medicine. 1997;337(17): 1195-1202. doi:10.1056/NEJM199710233371703

Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: What advantages does it offer?. Drugs. 2010;70(6): 643-650. doi:10.2165/11536100-000000000- 00000

Croghan IT, Hurt RD, Dakhil SR, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clinic Proceedings. 2007;82(2): 186-195. doi:10.4065/82.2.186

Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depres- sed patients with heart disease. The American Journal of Psychiatry. 1991;148(4): 512-516. doi:10.1176/ajp.148.4.512

Roose SP, Glassman AH, Giardina EG, et al. Cardiovascular effects of imipramine and bupro- pion in depressed patients with congestive heart failure. Journal of Clinical Psychopharmaco- logy. 1987;7(4): 247-251.

Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depres- sion: results of three clinical trials. Clinical Therapeutics. 1999;21(3): 454-463. doi:10.1016/ s0149-2918(00)88301-0

Motooka Y, Matsui T, Slaton RM, et al. Adverse events of smoking cessation treatments (nico- tine replacement therapy and non-nicotine prescription medication) and electronic cigaret- tes in the Food and Drug Administration adverse event reporting system, 2004-2016. SAGE Open Medicine. 2018;6:2050312118777953. doi:10.1177/2050312118777953

Moore T, Furberg CD, Glenmullen J, et al. Suicidal behavior and depression in smoking ces- sation treatments. PLoS ONE. 2011;6(11): e27016. doi:10.1371/journal.pone.0027016

US Food and Drug Administration. Highlights of Prescribing Information. Zyban (bupro- pion hydrochloride). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/la- bel/2014/020711s042lbl.pdf (accessed 23 February 2023).

Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicli- ne, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAG- LES): A double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037): 2507-2520. doi:10.1016/S0140-6736(16)30272-0

Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. European Heart Journal. 2003;24(10): 946-955. doi: 10.1016/s0195-668x(03)00003-4

Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acu- te cardiovascular disease. The American Journal of Medicine. 2006;119(12): 1080-1087. do- i:10.1016/j.amjmed.2006.04.024

Eisenberg MJ, Grandi SM, Gervais A, et al. Bupropion for smoking cessation in patients hos- pitalized with acute myocardial infarction: a randomized, placebo-controlled trial. Journal of the American College of Cardiology. 2013;61(5): 524-532. doi:10.1016/j.jacc.2012.08.1030

Carney G, Bassett K, Maclure M, et al. Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study. Addicti- on. 2020;115(8): 1534-1546. doi: 10.1111/add.14951

Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alp- ha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placeboand bupropion controlled trial with 1-year follow-up. Archives of Internal Medicine. 2006;166(15): 1561-1568. doi:10.1001/archinte.166.15.1561

Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine. 2006;166(15): 1571-1577. doi:10.1001/archinte.166.15.1571

Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acety- lcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking ces- sation: A randomized controlled trial. JAMA. 2006;296(1): 56-63. doi:10.1001/jama.296.1.56

Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA. 2006;296(1): 47-55. doi:10.1001/jama.296.1.47

Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA. 2006;296(1): 64-71. doi:10.1001/ jama.296.1.64

Hawk LW Jr, Ashare RL, Lohnes SF, et al. The effects of extended pre-quit varenicline treat- ment on smoking behavior and short-term abstinence: a randomized clinical trial. Clinical Pharmacology and Therapeutics. 2012;91(2): 172-180. doi:10.1038/clpt.2011.317

Hajek P, McRobbie HJ, Myers KE, et al. Use of varenicline for 4 weeks before quitting smo- king: decrease in ad lib smoking and increase in smoking cessation rates. Archives of Internal Medicine. 2011;171(8): 770-777. doi:10.1001/archinternmed.2011.138

Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: va- renicline. International Journal of Clinical Practice. 2006;60(5): 571-576. doi:10.1111/j.1368- 5031.2006.00955.x

Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: An alpha-4beta2 nicotinic receptor par- tial agonist for smoking cessation. Journal of Medicinal Chemistry. 2005;48(10): 3474-3477. doi:10.1021/jm050069n

Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking ces- sation in patients with cardiovascular disease: a randomized trial. Circulation. 2010; 121(2): 221-229. doi:10.1161/CIRCULATIONAHA.109.869008

Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking ces- sation. Cochrane Database of Systematic Reviews. 2012;4: CD006103. doi:https://doi. org/10.1002/14651858.CD006103.pub6

Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: A pre-post comparison with nicotine replacement therapy and an evalua- tion in those with mental illness. Addiction. 2008;103(1): 146-154. doi:10.1111/j.1360- 0443.2007.02083.x

Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smo- king cessation: results from a randomised open-label trial. Thorax. 2008;63(8): 717-724. doi:10.1136/thx.2007.090647

Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: A meta analysis of randomized controlled trials. Canadian Medical Association Journal. 2008;179(2): 135-144. doi:10.1503/cmaj.070256

Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Co- chrane Database of Systematic Reviews. 2008;(3): CD006103.

Josefberg H. Approval package for: application number NDA 21-928 [clinical safety review: varenicline tartrate]. Rockville (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2006.p.277,402. Available: www.accessdata.fda.gov/drugsatfdado- cs/nda/2006/021928 s000ChantixMedR.pdf (accessed 2023 Feb. 12).

Highlights of prescribing information: Chantix® (varenicline). New York (NY): Pfizer; 2006. Available: www.pfizer.com/files/products/uspi_chantix.pdf (accessed 2023 Jan. 14).

FDA Drug Safety Communication. Chantix (varenicline) may increase the risk of certain car- diovascular adverse events in patients with cardiovascular disease. Issued 22 July 2011. http:// www.fda.gov/Drugs/Drugsafety/ucm259161.htm. Accessed 5 Jan 2023.

Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Canadian Medical Association Jour- nal. 2011;183(12): 1359-1366. doi: 10.1503/cmaj.110218

Takagi H, Umemoto T. Varenicline: quantifying the risk. Canadidan Medical Association Jour- nal. 2011;183(12): 1404. doi: https://doi.org/10.1503/cmaj.111-2063

Woods DJ, Caswell MD. Varenicline: quantifying the risk. Canadidan Medical Association Journal. 2011;183(12): 1404-1407. doi:10.1503/cmaj.111-2064

Squire EN. Varenicline: quantifying the risk. Canadidan Medical Association Journal. 2011;183(12): 1404-1407. doi:10.1503/cmaj.111-2070

Samuels L. Varenicline: cardiovascular safety. Canadidan Medical Association Journal. 2011;183(12): 1407-1408. doi:10.1503/cmaj.111-2073

Foulds J, Russ C, Yu CR, et al. Effect of varenicline on individual nicotine withdrawal symp- toms: a combined analysis of eight randomized, placebo controlled trials. Nicotine&Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco. 2013;15(11): 1849-1857. doi:10.1093/ntr/ntt066

Ciciripini PM, Robinson JD, Karam-Hage M, et al. Effects of varenicline and bupropion sus- tained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70(5): 522-533. doi:10.1001/jamapsychiatry.2013.678

Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past majör depression: a randomized trial. Annals of Internal Medicine. 2013;159(6): 390-400. doi:10.7326/0003-4819-159-6-201309170-00005

Garza D, Murphy M, Tseng LJ, et al. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or pla- cebo. Biological Psychiatry. 2011;69(11): 1075-1082. doi:10.1016/j.biopsych.2010.12.005

Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of seri- ous cardiovascular events: nationwide cohort study. BMJ. 2012;345: e7176. doi:10.1136/bmj. e7176

Davies NM, Taylor GMJ, Taylor AE, et al. The effects of prescribing varenicline on two-year health outcomes: an observational cohort study using electronic medical records. Addiction. 2018;113(6): 1105-1116. doi:10.1111/add.14146

Kotz D, Viechtbauer W, Simpson CR, et al. Cardiovascular and neuropsychiatric risks of va- renicline and bupropion in smokers with chronic obstructive pulmonary disease. Thorax. 2017;72(10): 905-911. doi:10.1136/thoraxjnl-2017-210067

Cunningham FE, Hur K, Dong D, et al. A comparison of neuropsychiatric adverse events du- ring early treatment with varenicline or a nicotine patch. Addiction. 2016;111(7): 1283-1292. doi:10.1111/add.13329

Pasternak B, Svanstrom H, Hviid A. Use of varenicline versus bupropion and risk of psychiat- ric adverse events. Addiction. 2013;108(7): 1336-1343. doi:10.1111/add.12165

Harrison-Woolrych M, Maggo S, Tan M, et al. Cardiovascular events in patients taking vare- nicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Safety. 2012;35(1): 33-43. doi:10.2165/11597690-000000000-00000

Mazloom R, Eftekhari G, Rahimi M, et al. The role of alpha7 nicotinic acetylcholine receptor in modulation of heart rate dynamics in endotoxemic rats. PLoS One. 2013;8(12): e82251. doi:10.1371/journal.pone0082251

Moore C, Wang Y, Ramage AG. Cardiovascular effects of activation of central alpha7 and alpha4beta2 nAChRs: a role for vasopressin in anaesthetized rats. British Journal of Pharma- cology. 2008;153(8): 1728-1738. doi:10.1038/bjp.2008.47

Jutkiewicz EM, Rice KC, Carroll FI, et al. Patterns of nicotinic receptor antagonism II: cardi- ovascular effects in rats. Drug and Alcohol Dependence. 2013;131(3): 284-297. doi:10.1016/j. drugalcdep.2012.12.021

Rollema H, Russ C, Lee TC, et al. Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control. Nicotine&Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco. 2014;16(6): 733-742. doi:10.1093/ ntr/ntt208

Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with vare- nicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012;344: e2856. doi:10.1136/bmj.e2856

Kotz D, Viechtbauer W, Simpson C, et al. Cardiovascular and neuropsychiatric risks of vare- nicline: a retrospective cohort study. Lancet Respiratory Medicine. 2015;3(10):761-768. doi: 10.1016/S2213-2600(15)00320-3.